ATE262343T1 - Verwendung von gnrh analogen zur behandlung von schizophrenie - Google Patents

Verwendung von gnrh analogen zur behandlung von schizophrenie

Info

Publication number
ATE262343T1
ATE262343T1 AT99946505T AT99946505T ATE262343T1 AT E262343 T1 ATE262343 T1 AT E262343T1 AT 99946505 T AT99946505 T AT 99946505T AT 99946505 T AT99946505 T AT 99946505T AT E262343 T1 ATE262343 T1 AT E262343T1
Authority
AT
Austria
Prior art keywords
schizophrenia
treatment
gnrh analogue
gnrh
analogues
Prior art date
Application number
AT99946505T
Other languages
English (en)
Inventor
Tomas Eriksson
Original Assignee
Laekartjaenster I Vaestsverige
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laekartjaenster I Vaestsverige filed Critical Laekartjaenster I Vaestsverige
Application granted granted Critical
Publication of ATE262343T1 publication Critical patent/ATE262343T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Soundproofing, Sound Blocking, And Sound Damping (AREA)
  • Networks Using Active Elements (AREA)
AT99946505T 1998-08-26 1999-08-25 Verwendung von gnrh analogen zur behandlung von schizophrenie ATE262343T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802836A SE514606C2 (sv) 1998-08-26 1998-08-26 Läkemedel innehållande GnRH-analoger för behandling av schizofreni
PCT/SE1999/001441 WO2000012115A1 (en) 1998-08-26 1999-08-25 Use of composition in the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
ATE262343T1 true ATE262343T1 (de) 2004-04-15

Family

ID=20412345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946505T ATE262343T1 (de) 1998-08-26 1999-08-25 Verwendung von gnrh analogen zur behandlung von schizophrenie

Country Status (7)

Country Link
US (1) US6468973B1 (de)
EP (1) EP1115415B1 (de)
AT (1) ATE262343T1 (de)
AU (1) AU5890499A (de)
DE (1) DE69915849D1 (de)
SE (1) SE514606C2 (de)
WO (1) WO2000012115A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802438L (sv) * 1998-07-07 1999-07-19 Laekartjaenster I Vaestsverige Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
IL147138A0 (en) 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
DE3726324A1 (de) * 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
FR2661180B1 (fr) * 1990-04-23 1995-04-28 Inst Nat Sante Rech Med (hydroxyproline 9) lhrh, son procede d'obtention et application comme medicament.
RU2091390C1 (ru) * 1995-02-28 1997-09-27 Научно-исследовательский институт фармакологии РАН Замещенные пролилтирозины, обладающие психотропной активностью

Also Published As

Publication number Publication date
US6468973B1 (en) 2002-10-22
EP1115415A1 (de) 2001-07-18
DE69915849D1 (de) 2004-04-29
SE9802836L (sv) 2000-02-27
WO2000012115A1 (en) 2000-03-09
SE514606C2 (sv) 2001-03-19
EP1115415B1 (de) 2004-03-24
SE9802836D0 (sv) 1998-08-26
AU5890499A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
NO961326L (no) Inhibitorer av -amyloidproteinproduksjon
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
EA200500782A1 (ru) Лечение геморрагического шока
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
TR200200278T2 (tr) Kalsilitik bileşimler
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
ATE262343T1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
DE69927376D1 (de) Verwendung einer zusammensetzung enthaltend zumindest ein gnrh-analoges zur behandlung von zwangsneurotischen erkrankungen
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE398134T1 (de) Neue analoga von nitrobenzylthioinosin
DE69911052D1 (de) Verwendung von nicergoline zur behandlung der spastizität
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
DE60004473D1 (de) Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties